You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas: Hereditary Disorders
US FDA Approves Orkambi in Children with Cystic Fibrosis Ages 12 to <24 Months
2 September 2022 - - The US Food and Drug Administration approved expanded use of Orkambi (lumacaftor/ivacaftor) to include children with cystic fibrosis ages 12 to
Login
Related Headlines
First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant
Insmed completes adult patient enrolment in brensocatib pivotal ASPEN study
CF Foundation Invests Up to USD 15m in ReCode Therapeutics for Development of mRNA Therapy
Markels Named to Arcturus Therapeutics Board of Directors
SpliSense commences first-in-human, Phase 1/2 clinical trial of SPL84 to treat cystic fibrosis